WILMINGTON, Del., Nov 2 (Reuters) - Valeant Pharmaceuticals International Inc (NYSE:VRX) VRX.TO was sued on Wednesday on behalf of investors in Sprout Pharmaceuticals Inc, which it bought last year for $1 billion, over its alleged failure to successfully market the female libido pill Addyi.
According to a complaint filed in Delaware Chancery Court, Valeant neglected its obligations to market Addyi and priced the drug at $800 per month, twice as high as the market could bear.